Silence Therapeutics closes $201.3M public offering
Silence Therapeutics plc recently concluded a $201.3 million public offering of its American Depositary Shares (ADS). The offering closed at $13.50 per ADS, representing three ordinary shares of the biotechnology company. The deal included the full exercise of the underwriters' right to buy an additional 1.94 million ADSs. Key financial institutions, Jefferies, Morgan Stanley, Cantor, and William Blair, jointly acted as the book-running managers for the offering.
The transaction took place under a shelf registration statement that was approved by the U.S. Securities and Exchange Commission on May 27, 2026. Silence Therapeutics is currently in the clinical stage, focusing on developing short interfering RNA therapies.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
